Home » Oncology Firm BeOne Medicines Announces Rebrand, Global Expansion Plans

BeiGene Plans Rename to BeOne Medicines and Nasdaq Ticker Change to ONC

By

–

Oncology Firm BeOne Medicines Announces Rebrand, Global Expansion Plans

“Cancer, the leading cause of death worldwide, is costing individuals, families and communities profoundly.” So said John V. Oyler, co-founder, chairman and CEO of BeiGene, as the oncology company announced it will take the name BeOne Medicines Ltd.

The new name goes with a new logo. The company said both reflect a commitment to uniting communities in the fight against the disease. Oyler put the argument this way: “Individuals, families, scientists, clinicians, hospitals, lawmakers, corporations, and even nations cannot and will not stand alone against this devastating disease.”

The change needs shareholder approval. If it goes through, the company’s Nasdaq ticker will switch to “ONC”.

The numbers behind the rename

BeiGene says it has helped more than 1.4 million patients. It also says it is on track to move more than 10 new and potential therapies into clinical trials. The company describes the rename as part of a growth plan that has run since its start in 2010.

Recent results back that up, it said. Product sales rose in the United States and Europe, and total quarterly revenue reached $1 billion. In July the company opened a clinical R&D and manufacturing flagship facility at the Princeton West Innovation Campus in Hopewell, New Jersey, at a cost of $800 million.

The workforce is nearly 11,000 people. They have moved more than 20 molecules into clinical trials and won regulatory approvals on five continents. A global clinical team of more than 1,800 employees runs trials in more than 45 countries across Europe, North and South America, Australia and Asia. The company calls its approach “Fast to Proof of Concept”: it aims to produce early proof-of-concept data quickly, using the speed and cost advantages of its global operations.

Two lead products

BRUKINSA (zanubrutinib) carries the blood cancer business. The company says it has the widest range of indications among BTK inhibitors and is approved in more than 70 markets. In the U.S., BeiGene says it is the leading choice across approved B-cell malignancies. It also leads in new patients started on treatment for both first-line and relapsed or refractory chronic lymphocytic leukemia.

The drug is meant to anchor combination regimens too, paired with the late-stage BCL2 inhibitor sonorotoclax and with BGB-16673, a BTK-degrading agent.

In solid tumors, the company is pushing the PD-1 inhibitor TEVIMBRA (tislelizumab). It is also developing candidates for breast, lung and gastrointestinal cancers using antibody-drug conjugates, multispecific antibodies, targeted proteolytics and small molecule inhibitors.

Sources

Get breaking stories first on our Telegram channel.

More stories by

Most read

US News

Courts & Law

Immigration

US Travel & Outdoors